Novavax, Inc. said today that it has been added to the NASDAQ Biotechnology Index as of May 19, 2006. Novavax has traded on the exchange since July 10, 2001. "This is an important recognition of Novavax as a seasoned public company," said Novavax President and Chief Executive Officer, Dr. Rahul Singhvi. "We continue to move forward in our goal of developing unique vaccines that protect against contagious diseases, such as the H5N1 pandemic influenza, that endanger public health around the world."
PR Newswire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA Seeks Input on Risk-Benefit Reviews for Weight Loss Devices
The FDA said it “continues to receive a high volume of pre-submissions from industry requesting feedback about the necessary data to support pivotal clinical studies and marketing applications for a wide variety of device designs intended for weight loss.”
Costa Rican OTC Drugmaker Hit for Testing, Stability Program
The company said it would employ a third-party testing laboratory, but it didn’t provide a description of the test it would conduct.
FDAnews Drug Daily Bulletin
NOVAVAX ADDED TO NASDAQ BIOTECH INDEX
May 25, 2006
